Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Hikma Pharmaceuticals Plc - Key Facts

Hikma Pharmaceuticals Plc - Key Employees

Hikma Pharmaceuticals Plc - Key Employee Biographies

Hikma Pharmaceuticals Plc - Major Products and Services

Hikma Pharmaceuticals Plc - History

Hikma Pharmaceuticals Plc - Company Statement

Hikma Pharmaceuticals Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 – Company Analysis

Company Overview

Hikma Pharmaceuticals Plc - Business Description

Business Segment: Branded

Overview

Performance

Business Segment: Generics

Overview

Performance

Business Segment: Injectables

Overview

Performance

Business Segment: Others

Performance

Geographical Segment: Europe and Rest of the World

Performance

Geographical Segment: Middle East and North Africa

Performance

Geographical Segment: The UK

Performance

Geographical Segment: The US

Performance

R&D Overview

Hikma Pharmaceuticals Plc - Corporate Strategy

Hikma Pharmaceuticals Plc - SWOT Analysis

SWOT Analysis - Overview

Hikma Pharmaceuticals Plc - Strengths

Hikma Pharmaceuticals Plc - Weaknesses

Hikma Pharmaceuticals Plc - Opportunities

Hikma Pharmaceuticals Plc - Threats

Hikma Pharmaceuticals Plc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Hikma Pharmaceuticals Plc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Mar 13, 2019: Hikma delivers strong 2018 results and makes good strategic progress to position for future growth

Mar 12, 2019: Hikma board appoints Cynthia Schwalm as director

Nov 30, 2018: Hikma demonstrates support for US pharmacists and patient safety

Nov 09, 2018: Vectura and Hikma to jointly develop generic versions of GSK’s Ellipta

Nov 08, 2018: Hikma updates on current trading and raises 2018 guidance

Oct 04, 2018: Hikma Pharmaceuticals names Sagar Patel as European Commercial Head for Injectables

Oct 04, 2018: Hikma Appoints Global Head of Intellectual Property and US General Counsel

Aug 16, 2018: Hikma Pharmaceuticals appoints Kristy Ronco executive vice president, sales and marketing, generics

Aug 15, 2018: Hikma Pharmaceuticals: Half-year report

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and Rest of the World (ROW). Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

Mar 13,2019 Hikma delivers strong 2018 results and makes good strategic progress to position for future growth
Mar 12,2019 Hikma board appoints Cynthia Schwalm as director
Nov 30,2018 Hikma demonstrates support for US pharmacists and patient safety

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company